Chordia Therapeutics Inc. (JP:190A)
:190A
190A Stock Chart & Stats
¥108.00
-¥9.00(-2.81%)
At close: 4:00 PM EST
¥108.00
-¥9.00(-2.81%)
Day’s Range― - ―
52-Week Range¥98.00 - ¥276.00
Previous CloseN/A
Volume2.20M
Average Volume (3M)565.44K
Market Cap
¥9.04B
Enterprise Value¥6.49B
Total Cash (Recent Filing)¥2.55B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Apr 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.24
Shares Outstanding71,167,900
10 Day Avg. Volume542,310
30 Day Avg. Volume565,443
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Reported DebtA debt-free balance sheet materially reduces fixed financing obligations and interest risk, giving management flexibility to prioritize R&D or restructure spending without immediate refinancing pressure. Over 2–6 months this preserves optionality for partnerships, licensing, or measured capital raises.
Proven Revenue/profit Year (2023)Demonstrated ability to commercialize in 2023 shows the company can translate science into revenue and profit when programs or partnerships align. This operational proof point supports long-term credibility with partners and investors and raises the odds of future revenue if pipeline milestones are met.
Focused Oncology Small-molecule R&DA clear, specialized focus on oncology small molecules aligns with persistent, structural demand for cancer therapies and is attractive to partners and acquirers. Specialization concentrates R&D expertise, potentially accelerating development and enabling targeted collaborations that sustain long-term value creation.
Bears Say
Zero Recent RevenueReversion to zero revenue eliminates margin cushions and raises execution risk: ongoing R&D and clinical spend lack offsetting sales, increasing reliance on external funding. Over several months this reduces visibility on sustainable operations and heightens the probability of dilution or program cuts if milestones slip.
Sustained Cash BurnConsistent large negative operating and free cash flows indicate the company is consuming capital quickly. This materially shortens runway absent new funding, constrains ability to fund clinical trials internally, and increases likelihood of dilutive financing or partner-dependent strategies within a 2–6 month horizon.
Eroding Equity BaseA halving of equity and deeply negative ROE signal capital erosion from losses. This weakens the balance sheet, reduces financial flexibility despite no debt, and raises solvency concerns if losses persist. Over months, degraded equity limits strategic options and bargaining power with partners and investors.
Chordia Therapeutics Inc. News
190A FAQ
What was Chordia Therapeutics Inc.’s price range in the past 12 months?
Chordia Therapeutics Inc. lowest stock price was ¥98.00 and its highest was ¥276.00 in the past 12 months.
What is Chordia Therapeutics Inc.’s market cap?
Chordia Therapeutics Inc.’s market cap is ¥9.04B.
When is Chordia Therapeutics Inc.’s upcoming earnings report date?
Chordia Therapeutics Inc.’s upcoming earnings report date is Apr 10, 2026 which is in 10 days.
How were Chordia Therapeutics Inc.’s earnings last quarter?
Chordia Therapeutics Inc. released its earnings results on Jan 20, 2026. The company reported -¥4.24 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.24.
Is Chordia Therapeutics Inc. overvalued?
According to Wall Street analysts Chordia Therapeutics Inc.’s price is currently Overvalued.
Does Chordia Therapeutics Inc. pay dividends?
Chordia Therapeutics Inc. does not currently pay dividends.
What is Chordia Therapeutics Inc.’s EPS estimate?
Chordia Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chordia Therapeutics Inc. have?
Chordia Therapeutics Inc. has 71,167,900 shares outstanding.
What happened to Chordia Therapeutics Inc.’s price movement after its last earnings report?
Chordia Therapeutics Inc. reported an EPS of -¥4.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Chordia Therapeutics Inc.?
Currently, no hedge funds are holding shares in JP:190A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chordia Therapeutics Inc.
Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Tsubota Laboratory Incorporated
―
Shinnihonseiyaku Co., Ltd.
―
Heartseed, Inc.
―